The OraVital® System Now Guaranteed Effective for Treating Gingivitis and Mild to Moderate Periodontal Disease
-->
Toronto, CAN – February 14, 2017 – During the 2017 Chicago Midwinter Meeting, OraVital
Inc. will be unveiling a dental industry
first guarantee on its comprehensive OraVital® System, when applied
to the diagnosis and treatment of gingivitis and mild to moderate periodontal
disease. OraVital will be exhibiting at booth #1043 throughout the Chicago
Midwinter Meeting in McCormick Center.
According to OraVital CEO James Hyland,
DDS, “This is a first of a kind guarantee that states, when used as directed by
a OraVital® Certified Clinic, the OraVital® System will
predictably control the biofilm and oral infections that cause gingivitis and
mild to moderate periodontal disease with pockets less than or equal to 6 mm
prior to treatment.”
Under the terms of the
guarantee, if despite following the OraVital® System Protocol there
is not a noticeable improvement in the patient’s oral health (defined as an 87% and 79-84% reduction in BOP and
pockets respectively with no
pockets above 4 mm) the patient can be re-tested and re-treated free of
charge under the careful guidance of an OraVital® Clinical Coach who
will be assigned to that practice and patient.
The key to this
ground-breaking guarantee is the standardized training and implementation of OraVital’s
proprietary, non-invasive protocol consisting of its advanced BiofilmDNA™ microbiology test and
corresponding lab analysis, which guides the clinician in prescribing the
correct regimen of antibiotic/antifungal and antimicrobial rinses to effectively control the pathogenic
bacteria.
The
OraVital® System also includes the company’s recommended home
care regimen which is specially designed to keep oral biofilm and pathogens
under control. "If the bacteria in the biofilm are controlled
effectively by the practitioner in partnership with the patient, the oral infection
is controlled. The OraVital® System does this predictably,"
explains Dr. Hyland.
“With new research being
published almost daily linking exposure
to high risk periodontal pathogens to serious medical conditions such as
heart disease, arthritis, Alzheimer’s disease, rheumatoid arthritis and certain
forms of cancer, it’s more important than ever for us to ensure that the
OraVital® System is being used properly on our patients,” added Dr.
Hyland.
The OraVital®
System Guarantee will be officially extended to participating OraVital®
Certified Clinics throughout Canada and the United States on April 1st.
For more detailed information regarding terms and restrictions, please send an
inquiry to Guarantee@OraVital.com or
visit OraVital at booth #1043 during the 2017 Chicago Midwinter Meeting.
About OraVital Inc.
Headquartered in
Toronto, Canada, OraVital Inc. is the developer of the
comprehensive OraVital® System, which provides the most
accurate diagnosis and effective treatment of the oral infections that cause
periodontal disease, halitosis, peri-implantitis and caries. Consisting
of a proprietary protocol of advanced microbiology tests BiofilmDNA™ and BiofilmGS™
(Gram stain), combined with a personalized regimen of prescribed
antibiotic/antifungal and antimicrobial rinses used in a rinse and spit method which avoids the systemic effects of oral
antibiotics, the OraVital® System controls approximately 90% of
periodontal disease, halitosis, peri-implantitis and caries in as little as four weeks when used
as directed.* For more information, visit www.OraVital.com.
# # #
* These results are based upon a landmark study on 649 patients using the
OraVital® System. Results of this study were published in "Treatment
of oral malodor and periodontal disease using an antibiotic rinse." By Ken
Southward, DDS, FAGD and Anne Bosy, RRDH, MEd, MSc, - General Dentistry, July
2013.
Comments